Francis Lo - Mar 8, 2022 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief People Officer
Signature: /s/ Francis Lo by Eric Billings, attorney-in-fact
Stock symbol: ADPT
Transactions as of: Mar 8, 2022
Transactions value $: -$40,978
Form type: 4
Date filed: 3/10/2022, 03:05 PM
Previous filing: Mar 8, 2022
Next filing: Mar 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Sale	-$41K	-3.58K	-3.84%	$11.44	89.6K	Mar 8, 2022	Direct	F1, F2
holding	ADPT	Common Stock						2.5K	Mar 8, 2022	By You Jin Lee (spouse)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2021.
F2	The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.29 to 11.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Content

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2021.

The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.29 to 11.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.